Answer
In CYP2C19 normal metabolisers, mavacamten is metabolised primarily by CYP2C19 and to a lesser extent by CYP3A4, whereas in CYP2C19 poor metabolisers it is metabolised mostly by CYP3A4.
Sources for this answer
- Mavacamten BMS 2.5 mg, 5 mg, 10 mg, 15 mg hard capsulesBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 6Document updated
Sources checked